Beginning treatment for your lung cancer often brings questions surrounding what side effects will be experienced, according ...

Following the June 2025 FDA approval of Datroway, Dr. Jacob A. Sands explained the significance of the regulatory approval ...

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, ...

Compugen advances COM701 in ovarian cancer with strong partners, key catalysts ahead, and funding into 2027. Find out why ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today reported financial results ...